Download PDF
Thromb Haemost 1998; 80(06): 912-918
DOI: 10.1055/s-0037-1615388
Letters to the Editor
Schattauer GmbH

Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors

Nigel S. Key
1   University of Minnesota Hemophilia Treatment Center, Minneapolis, Minnesota
,
Louis M. Aledort
2   Mount Sinai Hospital, New York, New York
,
Diana Beardsley
3   Yale Hemophilia Center, New Haven, Connecticut
,
Herbert A. Cooper
4   UNC Hospital at Chapel Hill, Chapel Hill, North Carolina
,
George Davignon
5   Pediatric Hematology/Oncology, UCSD Medical Center, San Diego, California
,
Bruce M. Ewenstein
6   Hematology/Oncology Division, The Children’s Hospital, Boston, Massachusetts
,
Gerald S. Gilchrist
7   Hemophilia Center, Mayo Clinic, Rochester, Minnesota
,
Joan C. Gill
8   Great Lakes Hemophilia Foundation, Wauwatosa, Wisconsin
,
Bertil Glader
9   Division of Hematology/Oncology, Stanford University Medical Center, Stanford, California
,
W. Keith Hoots
10   MD Anderson Cancer Center, Houston, Texas
,
C. Thomas Kisker
11   University of Iowa Hospitals and Clinics, Iowa City, Iowa
,
Jeanne M. Lusher
12   Children’s Hospital Michigan, Detroit, Michigan
,
Cathy G. Rosenfield
13   New England Medical Center, Boston, Massachusetts
,
Amy Shapiro
14   JW Riley Hospital for Children, Indianapolis, Indiana
,
Horace Smith
15   Division of Hematology/Oncology, The Children’s Memorial Hospital, Chicago, Illinois
,
Edwin Taft
16   Albany Medical College, Albany, New York, USA
› Author Affiliations
Further Information

Publication History

Received 04 May 1998

Accepted after revision 28 August 1998

Publication Date:
07 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Objective. To assess the safety and efficacy of a fixed dose of recombinant activated factor VII (rFVIIa; NovoSeven™) in the home setting for mild to moderately severe joint, muscle, and mucocutaneous bleeding episodes in patients with haemophilia A or B with inhibitors. Design. Multicentre, open-label, single arm, phase III study of one year duration. Methods. Patients or their caregivers administered up to three doses of rFVIIa (90 μg/kg i.v.) at 3 h intervals within 8 h of the onset of a mild to moderate bleeding episode. Once the subject considered that rFVIIa had been “effective” with regard to haemostasis (after 1-3 injections), one further (maintenance) dose of rFVIIa was administered. Results. Of 60 patients enrolled, 56 experienced at least one bleed, and 46 completed the one year study. 614 of 877 bleeds (70%) were evaluable according to protocol definitions. Haemostasis was rated as “effective” in 92% (566/614) of evaluable bleeds after a mean of 2.2 injections. For successfully treated episodes, the time from onset of bleeding until administration of the first injection was 1.1 ± 2.0 h (mean ± SD). Twenty-four hours after initial successful response, haemostasis was reported as having been maintained in 95% of cases. Efficacy was comparable for muscle, joint and target joint, and muco-cutaneous bleeding episodes. In an intent-to-treat analysis of all 877 bleeding events, efficacy outcomes were equivalent to the evaluable bleeds, with an effective response in 88% of treated episodes. Treatment-related adverse events occurred in 32 (3% of all) bleeding episodes and consisted of re-bleeds/new bleeds in more than 50% (18/32) of these events. A single episode of superficial thrombophlebitis was the only thrombotic complication encountered, and there were no patient withdrawals due to adverse events. Development of FVII(a) antibodies could not be detected, and hypersensitivity reactions to rFVIIa were not reported. Conclusion. rFVIIa is effective and well tolerated when used in the home setting to treat mild to moderate bleeding episodes in patients with haemophilia A or B with inhibitors.

 

  • References

  • 1 Aledort LM. Inhibitors in hemophilia patients: current status and management.. Am J Hematol 1994; 47: 208-17.
    CrossrefPubMedGoogle Scholar
  • 2 Macik BG. Treatment of factor VIII inhibitors: products and strategies.. Semin Thromb Hemost 1993; 19: 13-24.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Parry DH, Bloom AL. Failure of factor VIII inhibitor bypassing activity (Feiba) to secure haemostasis in haemophiliac patients with antibodies.. J Clin Path 1978; 31: 1102-5.
    CrossrefPubMedGoogle Scholar
  • 4 Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. and the members of the French FEIBA study group.. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors.. Thromb Haemost 1997; 77: 1113-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Lusher JM. Thrombogenicity associated with factor IX complex concentrates.. Semin Hematol 1991; 28: 3 (suppl 6): 3-5.
    PubMedGoogle Scholar
  • 6 Rao LVM, Rapaport SI. Factor VIIa-catalysed activation of factor X independent of tissue factor. It’s possible significance for control of hemophilic bleeding by infused factor VIIa.. Blood 1990; 75: 1069-73.
    PubMedGoogle Scholar
  • 7 Hoffman M, Monroe DM, Roberts HR. Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high dose factor VIIa in hemophilia.. Blood 1994; 83: 38-42.
    PubMedGoogle Scholar
  • 8 Hedner U. Factor VIIa in the treatment of haemophilia. Blood Coag and Fibrinol. 1990: 307-17.
    PubMedGoogle Scholar
  • 9 Hedner U, Glazer S, Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders.. Transfusion Med Rev 1993; 7: 78-83.
    CrossrefPubMedGoogle Scholar
  • 10 Ingerslev J, Freidman D, Gastineau D, Gilchrist G, Johnsson H, Lucas G, McPherson J, Preston E, Scheibel E, Shuman M. Major surgery in haemophiliac patients using recombinant Factor VIIa.. Haemostasis 1996; 26 (Suppl. 01) 118-23.
    PubMedGoogle Scholar
  • 11 Molskov Bech R. Recombinant factor VIIa in joint and muscle bleeding episodes.. Haemostasis 1996; 26 (Suppl. 01) 135-8.
    PubMedGoogle Scholar
  • 12 Lusher JM. and the NovoSeven Compassionate Use Investigators.. Recombinant factor VIIa (Novoseven) in the treatment of internal bleeding in patients with FVIII and FIX inhibitors.. Haemostasis 1996; 26 (Suppl. 01) 124-30.
    PubMedGoogle Scholar
  • 13 Rice KM, Savidge GF. NovoSeven (recombinant Factor VIIa) in central nervous system bleeds.. Haemostasis 1996; 26 (Suppl. 01) 131-4.
    PubMedGoogle Scholar
  • 14 Schmidt ML, Gamerman S, Smith HE, Scott JP, DiMichele DM. Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors.. Am J Hematol 1994; 47: 36-40.
    CrossrefPubMedGoogle Scholar
  • 15 Macik BG, Hohneker J, Roberts HR, Griffin AM. Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophiliac patient with a high titer inhibitor.. Am J Hematol 1989; 32: 232-4.
    CrossrefPubMedGoogle Scholar
  • 16 Nicolaisen EM, Hansen LL, Poulsen F, Glazer S, Hedner U. Immunological aspects of recombinant factor VIIa (rFVIIa) in clinical use.. Thromb Haemost 1996; 76: 200-4.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Lusher JM. Dose-finding study of rFVIIa by: Schulman S. A report on the ISTH Satellite Symposium – Recombinant Coagulation Factor VIIa: Mechanism of Action and Clinical Experience held in New York,. July 10, 1993. Medicom Europe B. V., The Netherlands,; 1993 p 12.
    PubMedGoogle Scholar
  • 18 Pabinger I, Niessner H, Korninger C, Novotny C, Stain M, Kyrle PA, Lechner K. Home treatment of hemophilia.. Wien Klin Wochenschr 1987; 99: 773-7.
    PubMedGoogle Scholar
  • 19 Hilgartner MW, Cardi D, Goldberg I. Home Therapy.. In Haemophilia: Chapman and Hall Medical, London, 1997,. Forbes CD, Aledort L, Madhok R. eds. pp 171-81.
    PubMedGoogle Scholar
  • 20 Jones P. Haemophilia home therapy.. Haemostasis 1992; 22: 247-50.
    PubMedGoogle Scholar
  • 21 Varon D, Schulman S, Bashari D, Martinowitz U. Home therapy with continuous infusion of factor VIII after minor surgery or serious haemorrhage.. Haemophilia 1996; 2: 207-10.
    CrossrefPubMedGoogle Scholar
  • 22 Ross-Degnan D, Soumerai SB, Avorn J, Bohn RL, Bright R, Aledort LM. Hemophilia home treatment: Economic analysis and implications for health policy.. Int J Technol Assess Health Care 1995; 11: 327-44.
    CrossrefPubMedGoogle Scholar
  • 23 Hansen LL, Nielsen FE, Hedner U. Validation of method for determination of recombinant FVIIa coagulant activity in plasma using a one-stage clotting assay.. Thromb Haemost, 1993; 69 (06) 1008 (abstr 1162).
    PubMedGoogle Scholar
  • 24 Ingerslev J, Feldstedt M, Sindet-Pedersen S. Control of haemostasis with recombinant factor VIIa in patients with inhibitors to factor VIII.. Lancet 1991; 338: 831-3.
    PubMedGoogle Scholar
  • 25 Roberts H. Clinical experience with recombinant factor VIIa (NovoSeven): summary of efficacy and safety.. Haemophilia. 1996 2. 01 63 Abstract 240.
    PubMedGoogle Scholar
  • 26 Hay CRM, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study.. Thromb Haemost 1997; 78: 1463-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Schwartz RS, Ewing NP, Gorenc TJ, Spero JA. Comparative efficacy of nonheated and heat-treated factor IX complex concentrate in treatment of hemophiliacs with inhibitors.. Am J Hematol 1989; 30 (01) 22-6.
    CrossrefPubMedGoogle Scholar
  • 28 Hay CRM, Lozier JN, Lee CA, Laffan M, Tradati F, Santagostino E, Ciavarella N, Schiavoni M, Fukui H, Yoshioka A, Teitel J, Mannucci PM, Kasper CK. Safety profile of porcine factor VIII and its use as hospital and home therapy for patients with haemophilia A and inhibitors. The results of an international survey.. Thromb Haemost 1996; 75: 25-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Lusher JM, Blatt PM, Penner JA, Aledort LM, Levine PH, White GC, Warrier AI, Whitehurst DA. Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII.. Blood 1983; 62 (05) 1135-8.
    PubMedGoogle Scholar
  • 30 Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia.. Br J Haematol 1996; 92: 973-8.
    CrossrefPubMedGoogle Scholar
  • 31 Smit C, Rosendaal FR, Varekamp I, Bröcker-Vriends A, Van Dijck H, Suurmeijer T PBM, Briët E. Physical condition, longevity, and social performance of Dutch haemophiliacs.. BMJ 1989; 298: 235-8.
    CrossrefPubMedGoogle Scholar
  • 32 Association of Hemophilia Clinic Directors of Canada.. Hemophilia and von Willebrand’s disease: 1. Diagnosis, comprehensive care and assessment.. Can Med Assoc J 1995; 153: 19-25.
    PubMedGoogle Scholar
  • 33 Aledort LM, Haschmeyer RH, Pettersson H. and the orthopaedic outcome study group.. A longitudinal study of orthopaedic outcomes for severe factor VIII-deficient haemophiliacs.. J Int Med 1994; 236: 391-9.
    CrossrefPubMedGoogle Scholar